Evidence map›Paper›PMID 41243071›Full record

Trial reportJournal of thrombosis and thrombolysis2026

Sex differences among elderly ACS patients undergoing percutaneous coronary intervention receiving Ticagrelor 60 mg vs. 90 mg.

Raffaele Piccolo, Angelo Laino, Antonio Pio Vitale, Mario Enrico Canonico, Marisa Avvedimento, Fiorenzo Simonetti, Roberta Paolillo, Fabrizio Dal Piaz, Bruno Charlier, Alessandra Spinelli and 8 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04739384 (Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04739384 phase3completednot on this map

Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)

TypeinterventionalSponsorFederico II UniversityRan2021 to 2022Enrolled50ConditionsAcute Coronary Syndrome, STEMI, NSTEMI, Coronary Artery DiseaseArmsTicagrelor 90mg, Ticagrelor 60 mg
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Raffaele PiccoloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy. Raffaele.Piccolo@unina.it.
Angelo LainoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Antonio Pio VitaleDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Mario Enrico CanonicoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Marisa AvvedimentoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Fiorenzo SimonettiDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Roberta PaolilloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Fabrizio Dal PiazDepartment of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Bruno CharlierDepartment of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Alessandra SpinelliDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Stefano CristianoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Luigi Di SerafinoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Plinio CirilloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Giuseppe GargiuloDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Anna FranzoneDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.
Amelia FilippelliDepartment of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Valeria ContiDepartment of Medicine, Surgery and Dentistry, Scuola Medica Salernitana, University of Salerno, Baronissi, SA, Italy.
Giovanni EspositoDepartment of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

No sex-based data are available on the pharmacodynamic and pharmacokinetic profile of ticagrelor 60 mg twice daily as alternative to its standard dose during the early phase after acute coronary syndrome (ACS). This post-hoc study is a sex-based secondary analysis of the PLINY THE ELDER randomized, crossover trial (NCT04739384), which compared ticagrelor 60 vs. 90 mg in elderly patients with ACS undergoing percutaneous coronary intervention (PCI). The primary endpoint was the pre-dose P2Y

Indexed as

Acute Coronary SyndromePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsTicagrelorAgedCross-Over StudiesFemaleHumansMalePurinergic P2Y Receptor AntagonistsSex CharacteristicsSex FactorsPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTicagrelorAcute Coronary SyndromesElderlyPlateletsSexTicagrelor

Identifiers

PMID41243071
PMCPMC13246881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.